SMARTER INVESTMENT IN THE RESEARCH LONG GAME Government support for health and medical researchers and innovators needing investment cycle review
With
Nadia Levin, CEO
Research Australia
OP-ED SEGMENT
Filmed in Sydney | April 2026
In this Op-Ed, Nadia Levin, CEO of Research Australia, spoke with the Australian Health Journal about the need for smarter and more strategic investment in Australia’s health and medical research sector.
Levin argued that Australia’s approach to health and medical research has been shaped too heavily by short-term political cycles rather than a long-term national vision. She emphasised that meaningful progress in science, innovation, and healthcare requires sustained investment over many years.
According to Levin, health and medical research should not be viewed simply as a social good, but as a major driver of economic growth, productivity, and national resilience. She highlighted that every preventable hospital admission, faster diagnosis, or locally developed medical product contributes to economic performance.
Research Australia estimates that for every dollar invested in health and medical research, the Australian economy receives around four dollars in return.
Levin pointed to Australia’s past achievements, including the development of IVF, the cochlear implant, the HPV vaccine, and ultrasound imaging, as examples of how research can improve lives while creating industries and export opportunities.
A major focus in the need to strengthen the entire research pipeline, from early-stage discovery through to clinical translation, commercialisation, and integration into healthcare systems. Research Australia in a media release March 2026, noted that while the Medical Research Future Fund was created to distribute around $1 billion annually, it is currently providing only about $650 million each year despite holding approximately $24.5 billion.
Levin referenced costings from the Parliamentary Budget Office (PBO), commissioned by Dr Monique Ryan MP, showing the fund could distribute up to $1.4 billion annually without reducing its capital base, arguing that the money, demand, and need already exist, but stronger government commitment is required.
Source: Adapted from Research Australia media release March 2026
-
Recognising clinical trials and the people behind the research
Australia’s clinical trials community came together to celebrate outstanding research and recognise the people and teams making a meaningful difference to healthcare at the 2026 ACTA Trial of the Year Awards.
Now in its 10th year, the awards continue to shine a light on investigator-led clinical trials and initiatives that are improving clinical practice, influencing healthcare policy and delivering better outcomes for patients across Australia and beyond.
-
Dentist creates app to democratise oral health care
In this People In Health Care segment, Dr Gadiyar spoke to Australian Health Journal on how she hopes the app will help increase the number of people seeking dental treatment from the current 47% level in Australia. To date, 120,000 users have downloaded the app with more than 50 dental practices signed up with Smilo.ai to receive individual enquiries or seek dental treatment.
-
National incubator shifts into gear, announcing vaccine and infectious disease innovation cohort
Biointelect Venturer has announced six Australian infectious disease innovations will share $10.48 million in the incubator’s first funding round giving the successful research teams the ability to advance their early-stage breakthroughs to commercial and investment readiness.
